Health Catalyst (NASDAQ:HCAT) Given New $10.50 Price Target at Citigroup

Health Catalyst (NASDAQ:HCAT) had its target price raised by Citigroup from $9.00 to $10.50 in a report released on Wednesday morning,Benzinga reports. They currently have a buy rating on the stock.

Other analysts have also issued reports about the company. Cantor Fitzgerald reiterated an “overweight” rating and set a $16.00 price target on shares of Health Catalyst in a report on Friday, October 4th. Royal Bank of Canada boosted their price target on shares of Health Catalyst from $8.00 to $9.00 and gave the stock a “sector perform” rating in a report on Thursday, November 7th. Evercore ISI increased their price target on shares of Health Catalyst from $8.00 to $10.00 and gave the company an “outperform” rating in a research report on Tuesday, October 8th. Stephens reduced their target price on shares of Health Catalyst from $8.00 to $7.00 and set an “equal weight” rating for the company in a research report on Thursday, August 8th. Finally, JPMorgan Chase & Co. upped their price objective on Health Catalyst from $10.00 to $13.00 and gave the company an “overweight” rating in a research note on Wednesday, September 4th. Three research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $11.71.

Health Catalyst Trading Down 9.5 %

NASDAQ HCAT opened at $7.65 on Wednesday. The company has a current ratio of 1.41, a quick ratio of 1.41 and a debt-to-equity ratio of 0.32. The business has a fifty day simple moving average of $8.16 and a 200 day simple moving average of $7.22. Health Catalyst has a 12 month low of $5.42 and a 12 month high of $11.41. The firm has a market capitalization of $465.50 million, a P/E ratio of -5.67 and a beta of 1.32.

Health Catalyst (NASDAQ:HCAT) last issued its quarterly earnings data on Wednesday, November 6th. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). Health Catalyst had a negative return on equity of 7.51% and a negative net margin of 26.20%. The firm had revenue of $76.40 million during the quarter, compared to the consensus estimate of $76.27 million. During the same period in the previous year, the company posted ($0.22) earnings per share. The company’s revenue for the quarter was up 3.5% on a year-over-year basis. On average, analysts predict that Health Catalyst will post -0.35 EPS for the current fiscal year.

Insider Activity at Health Catalyst

In other news, COO Daniel Lesueur sold 8,137 shares of the company’s stock in a transaction dated Wednesday, September 4th. The stock was sold at an average price of $7.58, for a total transaction of $61,678.46. Following the sale, the chief operating officer now directly owns 140,108 shares in the company, valued at $1,062,018.64. This represents a 5.49 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Kevin Lee Freeman sold 7,500 shares of the firm’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $7.22, for a total transaction of $54,150.00. Following the completion of the transaction, the insider now owns 255,881 shares of the company’s stock, valued at $1,847,460.82. This trade represents a 2.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 34,068 shares of company stock worth $257,555. 2.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On Health Catalyst

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Primecap Management Co. CA boosted its position in shares of Health Catalyst by 14.7% during the 2nd quarter. Primecap Management Co. CA now owns 2,379,462 shares of the company’s stock valued at $15,205,000 after acquiring an additional 305,079 shares during the last quarter. Kennedy Capital Management LLC bought a new stake in Health Catalyst during the first quarter valued at approximately $8,780,000. Acadian Asset Management LLC raised its position in shares of Health Catalyst by 38.3% during the 1st quarter. Acadian Asset Management LLC now owns 724,560 shares of the company’s stock valued at $5,453,000 after buying an additional 200,494 shares in the last quarter. Essex Investment Management Co. LLC bought a new stake in shares of Health Catalyst during the 3rd quarter worth $2,012,000. Finally, AQR Capital Management LLC bought a new position in Health Catalyst in the second quarter valued at $564,000. 85.00% of the stock is currently owned by hedge funds and other institutional investors.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.